BCOP Self-Study

Self-Study 2025 Release I Bundle

On-demand The 2025 BCOP Self-Study Bundle Release I offers 9.5 BCOP CE hours and ACPE CE hours. Learn more

Self-Study 2025 Release I: Treatment of Non-Melanoma Skin Cancers

On-demand The purpose of this course is to review treatment options in the management of non-melanoma skin cancers. This will include a review of the role of immunotherapy and hedgehog pathway inhibitors at different stages, and will include efficacy and safety data, as well as considerations for patient monitoring and toxicity management. Learn more

Self-Study 2025 Release I: Anxiety and Depression in Adult Survivors of Cancer

On-demand In this module, participants will explore risk factors and contributors to anxiety and depression in adult persons with cancer, identify scoring tools for assessment, and review data surrounding pharmacologic and non-pharmacologic treatment modalities to address anxiety and depression, including the utilization of cannabis. Learn more

Self-Study 2025 Release I: Targeting HER2 in Non-Breast Solid Tumors

On-demand The purpose of this course is to look at the extensive research conducted to look at targeted HER2 therapies in a variety of disease states. Learn more

Self-Study 2025 Release I: Germline Genetic Testing in Patients with Cancer

On-demand This session will provide an overview of the prevalence of germline cancer susceptibility mutations in those who are diagnosed with cancer. Learn more

Self-Study 2025 Release I: Myeloproliferative Neoplasms - A Focus on JAK Inhibitors in Myelofibrosis

On-demand While research continues beyond JAK inhibitors to new targets, sequencing of these agents in the event of inadequate response or loss of response is an area of ongoing interest. Learn more

Self Study 2024 Release II Bundle

On-demand The 2024 BCOP Self-Study Bundle Release II offers 10 BCOP CE hours and ACPE CE hours. Learn more

Self Study 2024 Release II: Bispecific T-Cell Engager Therapy: Hematologic Malignancies and Solid Tumors

On-demand This module provides an overview of the evidence supporting their approved indications and discusses current recommendations and ongoing areas of research for this class of agents. Learn more

Self Study 2024 Release II: Treatment Updates in Myelodysplastic Syndrome

On-demand In this module, participants will evaluate current and potential future treatment advances in the management of both lower- and higher-risk MDS. Learn more

Self Study 2024 Release II: Adolescent/Young Adult Survivorship (Healthcare Disparities as well as Long-Term Mortality)

On-demand This module will explore the challenges faced by AYA survivors of cancer including physical, psychological, and social burdens, risk of comorbidity development, and factors influencing increased mortality and reduced survival. Learn more

Self Study 2024 Release II: ESR1 Mutations in Metastatic Breast Cancer

On-demand Endocrine therapy is the backbone of treatment in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative, metastatic breast cancer (mBC), but resistance universally develops. Our understanding of the role of mutations in the gene that encodes for the estrogen receptor, ESR1, in resistance to endocrine therapies has grown in the last 5 years. Patients acquire mutations in the ligand binding domain for ESR1 after treatment with endocrine therapy, leading to resistance to aromatase inhibitors. Learn more

Self Study 2024 Release II: Neoadjuvant Immunotherapy Updates in NSCLC, Colon, and Rectal Cancer

On-demand Review updates for use of ICI in the neoadjuvant setting. This will include a review of safety and efficacy data of pembrolizumab in NSCLC, review of predictive biomarkers in rectal and colon cancer, and safety and efficacy data of dostarlimab in rectal cancer. Learn more